Sinclair Pharma Plc completes share issue raising gross proceeds of £19 million

On 4 October 2010, the shareholders of Sinclair Pharma Plc ("Sinclair Pharma") approved a firm placing and placing and open offer to raise gross proceeds of £19 million. Application was made for the new ordinary shares to be admitted to trading on both the London Stock Exchange's main market for listed securities and on the Eurolist of Euronext, Paris with effect from 6 October 2010.   Sinclair Pharma is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems.  Fasken Martineau advised Sinclair Pharma on this transaction with a team comprised of June Paddock, Abayomi Akinjide, Peter Rhodes and Michael Kashis.